From: Castagno, Paula

To: Beckhardt, Stacey; Catherine Collier; Jacqueline Davis

Sent: 3/23/2007 10:36:31 PM

Subject: my ppt so far

Attachments: HCPAB presentation 03 07.ppt

Slides 1-19 Michael's (now my) section

-Not sure how much data to review...let me know your thoughts (some data slides need updating – and prettying)

Slides 20-21 my 1st section

-review of FENTORA tools for feedback (need to make sure we have copies of everything there)

Slides 22-30 BTP part 1

-review current campaign, recent market research, play dvd of focus groups, end with revised messaging for discussion

Slide 31-39 BTP part 2

-reveal new concept and all planned BTP educational activities by audience and get feedback

Will we have internet access in the room?

Ignore the rest of the slides – its back up info.

Tx,

Paula Castagno

Assoc. Director, Pain Franchise

Cephalon

41 Moores Road

Frazer, PA 19355

ph 610-738-6517

fx 610-738-6641

PLAINTIFFS TRIAL EXHIBIT
P-18545_00001

Cephalon Pain Franchise

Health Care Professional Advisory Board


March 30 – April 1, 2007




Objectives

- Review current FENTORA marketplace
- Review 2007 Issues and CSFs
- Discuss potential opportunities and barriers for FENTORA & Assess marketplace needs





Big market – down slightly due to LAO generic entry LAO make up biggest value (but slightly declining due to generic entry) Actiq makes up the majority of pure SAO value (only branded pure SAO in 2005), but only captured a small part of volume Combo SAOs make up biggest volume (mostly generic) – a large percentage used for acute pain



Pure SAOs have strong growth in terms of both Value & Volume Fentanyl made up the largest value in 2005 due to branded Actiq, all other compounds are generic Oxycodone dominates the Pure SAO mkt in terms of volume Fentanyl is often perceived as a more potent analgesic and held in reserve

Actiq makes up the majority of Pure SAO value (only branded in 2005), but only minimal volume Oxycodone: 8 generics, OxyIR®, Oxyfast®, Roxicodone®, Oxydose®

Morphine: 9 generics, MSIR®, Roxanol™ Hydromorphone: 16 generics, Dilaudid®

Fentanyl: Actiq®


BTP Treatment Patterns

- The most common treatment choice is to increase the dose of LAOs regardless of # of episodes
- The next most common approach is to either increase the frequency or dose of the SAO
- Switching to an alternative SAO is typically the last course of action

	# of B1	# of BTP Episodes	
Typical Course of Action	≤3	≥ 4	
Increase dose of LAO	34%	64%	
Increase frequency of LAO	7%	12%	
Increase frequency of SAO	21%	10%	
Switch the LAO	2%	7%	
Increase dose of SAO	28%	4%	
Switch the SAO	3%	2%	

Source: GfK Market Measures - 05





BDSI – Bema (fentanyl) is scheduled for early 3Q'08 launch - mucoadhesive disc designed to rapidly deliver the active ingredient across the buccal mucosa of the mouth

Key Environmental Trends

Key Factors

Current Dynamics

Economic

- · Unfavorable reimbursement environment
- · Payers are increasing restrictions to drive usage to less costly drugs
- Payers don't understand BTP

Social / Cultural

- Abuse and diversion are top-of-mind topics for physicians and other stakeholders
- Society (including many physicians) are critical of their patients' inability to cope with their pain
- Pain patients feel misunderstood by physicians, friends, and family and often become frustrated and depressed
- Patients are often looking for an easy short-term solution to their pain and are not focused on long-term wellness

Political / Governmental

- Opioid abuse is a hot political issue and physicians are under significant scrutiny about proper use of opioids
- FDA is hypersensitive about safety issues in a post-Cox II and OxyContin world

Legal

- DEA guidelines for writing opioids are unclear
- Ongoing issues between the DEA and various pain societies
- · Perception that more physicians getting sued/licenses taken away

Clinical / Technological

- Lack of significant practical advancements in pain medicine
- · New drugs, routes of administration, and improved control of side effects
- New insights into the anatomy and physiology of pain perception
- Greater understanding of how to integrate pharmacotherapeutic, psychological, and behavioral pain management approaches
- New tracking technology for packaging to avoid diversion



Social: BTP Awareness

Prescribers


- BTP is a relatively new disease state, only generally recognized by top tier opioid prescribers
 - ► First in print in 1990 (Portenoy survey)
 - ► Actiq first product indicated for BTP, launched 1998


Patients


Communication Gap exists between Prescribers & Patients













Prior to Oct 2006 Actiq was sole ROO Consistent Value growth (more recently due to price increases) Strong Volume growth up to 2004 (reached plateau)


As of Oct 2006


Generic OTFC introduced
Captured 21% of volume
FENTORA introduced
Captured 13% of volume
Fentanyl made up the largest value in 2005 due to branded Actiq, all other compounds are generic
But in terms of volume, oxycodone makes up the majority of the pure SAO mkt
Fentanyl is often perceived as a more potent analgesic and held in reserve



Importance of timing: FENTORA launch in concert w/ generic entry 4th qrtr launch difficult - seasonality













Feedback

- HCPs
 - ► Titration and dosing questions/issues?
 - ► Strengths higher dose? 300mcg?
 - ▶ Issues with tablets boxed in 28s?
- Patients
 - ► Patient administration and titration sheet (need copies there for review)
 - ► Application site issues?
 - ► Taste issues?
 - ► Catalina Newsletters (need copies there)
 - ► Patient FAQs (need copies there)
 - ► Patient Starter Kit (need copies there)





CSF: Improve BTP awareness and understanding of treatment options among physicians and patients

Strategy

- Continue to establish BTP as a distinct clinical problem among appropriate physicians
- Facilitate dialogue between physicians and patients to improve the proper diagnosis and treatment of BTP
- Support BTP educational initiatives

Educational Activities

- BTP campaign
 - ► Journal ad & targeted media
 - ►DA Convention Booth
 - ▶BTP website
 - ▶ Direct Mail
 - ►PR initiatives (outreach, etc)
- In-office patient material




Breakthrough Pain Campaign



You've all seen the shark – our current BTP campaign to raise awareness of this disease state. This is and has been a CSF for us and we are committed to expanding and evolving this campaign. It is currently geared toward HCPs and we are ready to broaden our audience – including patients. We sent our operatives out to conduct market research to understand how patients and physicians define, describe, think, & feel about BTP. Here is what we learned.





As you just heard, the research highlighted the wide communication gap between patients and physicians Patient inability to describe their pain effectively

Time is short during the office visit

They are not speaking the same language

There is distrust on both sides

So we are rolling out a disease awareness campaign and tactical plan designed to raise awareness, educate and bridge that communication gap – to own that doctor visit and make it more productive.

Discussion of BTP Market Research Video


Messag	ies to	Bridge	the Ga	b

Topic	Primary Message	Secondary Messages
Definition	Breakthrough pain (BTP) is a sudden flare of pain that "breaks through" the medicine taken for all-day pain.	Chronic pain often has 2 parts: persistent pain and BTP
Characteristics	BTP can be brought on by doing everyday activities.	 BTP can be triggered by activities as simple as getting out of bed, taking a walk, picking up a bag of groceries Some BTP episodes can be predicted, others come out of nowhere BTP episodes usually come on fast, peaking in as little as 3 minutes. Other episodes may escalate more slowly BTP can occur several times per day
Impact	BTP is disruptive.	 Even when persistent pain is well controlled, BTP can prevent patients from doing everyday activities Patients with BTP often feel like nobody can understand or appreciate what they're going through Patients with BTP may feel anxious and depressed Over time, BTP can harm relationships with friends and family. Patients feel like complainers

Messages to Bridge the Gap

Topic	Primary Message	Secondary Messages
Legitimizing the Condition	BTP needs to be understood as a separate condition.	 Most pain patients on all-day pain medication experience BTP BTP is not merely a symptom of chronic pain
Treatment	By separating chronic pain into persistent pain and BTP, doctors can assess and treat each problem individually and give better care.	 Since pain has peaks and valleys, it can be treated with 2 medicines: one for persistent pain and a second for the flares of BTP The most appropriate treatment for BTP would begin to work quickly and last about as long as a BTP episode
Patient-Doctor Relationship	Patients and doctors must work together to fight BTP.	 BTP patients may have a hard time explaining what's been happening to them during a brief doctor visit Patients must be able to provide details of their pain so doctors can better help Patients can prepare for a doctor visit by using a pain Journal







Here is our BTP campaign – which will be used in journals, conventions, and online at BTP.com. The roll out of this campaign is May. It tested very well with physicians and patients and speaks to both the emotional aspect of BTP and the idea that it is a very real disease that needs independent assessment.

BTP Activities

- HCP Education
 - ▶BTP.com Medical Professional Site
 - Articles, tools, tips, on proper assessment of BTP and how to maximize patient/HCP communication
 - Alternative treatment discussions
 - Risks of using opioids
 - Video clips of Q&A, patient interviews, etc.
 - eNewsletter sign-up
 - ▶ Epocrates alerts about BTP
 - ► Educate via AAFP journal to educate on BTP



BTP Activities

- HCP Education
 - ▶ BTP booth presence (new concept @ APS)
 - AAPM, ASPMN, ONS, APS, AAPM&R, ASA
 - AMCP & ASHP managed care meetings
 - Staffed by Medical Science Liaisons
 - Booth materials include
 - →BTP brochure & chronic pain assessment tool (need copies there to review)
 - →Portenoy reprints
 - → Making Pain Talk Painless (patient piece need copies)
 - → Shareyourpain.org postcard (patient piece need copies)
 - →Other ideas????



BTP Activities


- HCP Education
 - ▶Online assessment tool (internet access?)



BTP Activities

- Patient Education
 - ▶BTP.com patient site (internet access?)
 - Review planned site map for patients
 - ▶ Online assessment tool (internet access?)
 - ► Catalina newsletter on BTP (need copies)
 - ►SYP.org (internet access??)
 - ► Krames type brochures (need copies there)
 - ► Potential articles in Readers Digest, Womans World, Prevention







Here is a look at one of our online initiatives to drive traffic to BTP.com. This is SYP.org and it will provide patients a forum to describe their pain using refrigerator magnets – it will get them used to using descriptive words for their BTP, and get patients talking about BTP. It also allows patients to share their "refrigerators" with others in an online pain community so they don't feel so alone. And of course it links to BTP.com so they can learn more.












FENTORA Strategic Update

- Shipments
 - ▶ \$10.7M (February 2007)
- Prescriptions
 - ► Monthly TRx (Feb): 6,546
 - ▶ Market Share (Feb): 24% of ROO market
- Studies
 - ▶ Low Back BTP (3042): Pub *CMRO* 12/06
 - ▶ Neuro BTP (3041): Press Rel 1/8/07, AAN Poster 5/07, Pub Clin Ther 5/07
 - ► Efficacy Ca-BTP (3039 onset): ASCO Abstract 6/07, Pub J Supt Onc 3Q07
 - ▶ Buccal/Sublingual PK (1043): Top line results 2/07
- Regulatory Activities
 - ► S-001 Modifications to PI, Med Guide, Carton, Blister: PDUFA 4/26/07
 - ► S-002 300 mcg tablet: Approved 3/2/07, commercialization tent 4Q07
 - ► S-003 3039 (onset data): submitted 3/2/07 (6 mth review)
 - ► S-004 sNDA Non-Ca: submitting 3Q07 (10 mth review)














Importance of timing: FENTORA launch in concert w/ generic entry



























































To learn more about BTP, visit www.breakthroughpain.com





To learn more about BTP, visit www.breakthroughpain.com